Enovis Corporation (ENOV)
Market Cap | 2.41B |
Revenue (ttm) | 2.00B |
Net Income (ttm) | -119.19M |
Shares Out | 55.88M |
EPS (ttm) | -2.18 |
PE Ratio | n/a |
Forward PE | 14.23 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 631,750 |
Open | 42.02 |
Previous Close | 42.49 |
Day's Range | 42.02 - 43.59 |
52-Week Range | 38.27 - 65.03 |
Beta | 2.02 |
Analysts | Strong Buy |
Price Target | 67.00 (+55.38%) |
Earnings Date | Nov 6, 2024 |
About ENOV
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular th... [Read more]
Financial Performance
In 2023, Enovis's revenue was $1.71 billion, an increase of 9.22% compared to the previous year's $1.56 billion. Losses were -$33.26 million, 150.2% more than in 2022.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ENOV stock is "Strong Buy." The 12-month stock price forecast is $67.0, which is an increase of 55.38% from the latest price.
News
Enovis Corporation: Reasonably Valued With Caveats
Medical device concern Enovis Corporation's Q3 results were released on November 6th, showing positive financial performance and future growth prospects. Analysts, including Wells Fargo and Needham, r...
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate i...
Enovis Corporation (ENOV) Q3 2024 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV) Q3 2024 Results Conference Call November 6, 2024 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Be...
Enovis Announces Third Quarter 2024 Results
Wilmington, DE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ...
Enovis to Host Third Quarter 2024 Results Conference Call on November 6th
Wilmington, DE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and...
Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says
JMP Securities initiated coverage on Enovis Corporation ENOV, a medical technology company focusing on orthopedics.
Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position...
Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures
First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller. First surgeries using EMPOWR Revision Knee™ with ...
Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability
Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now I...
Enovis Announces Second Quarter 2024 Results
Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter...
Enovis Announces Time Change for Second Quarter 2024 Results Conference Call
Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming earnin...
Enovis to Host Second Quarter 2024 Results Conference Call on August 7th
Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and...
Enovis Languishing Despite Respectable Performance
Enovis stock performance has continued to lag larger sector peers despite respectable results from the Reconstructive (orthopedic device) business. The Street may well be concerned that Enovis cannot ...
Enovis™ Releases AltiVate Reverse® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate Reverse®
New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity a...
Top 3 Health Care Stocks That Could Blast Off In June
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Enovis Corporation (ENOV) Q1 2024 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Kyle Rose - VP, IR Matthew Trerotola - CEO Phillip Berry - CFO Conference Call Participants...
Enovis Announces First Quarter 2024 Results
Wilmington, DE, May 02, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter...
Enovis to Host First Quarter 2024 Results Conference Call on May 2nd
Wilmington, DE, April 17, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call an...
Enovis Corporation (ENOV) Q4 2023 Earnings Call Transcript
Enovis Corporation (ENOV) Q4 2023 Earnings Call Transcript
Enovis Announces Fourth Quarter and Full Year 2023 Results
Wilmington, DE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarte...
Enovis™ to Highlight Latest Technologies Across the Orthopedic Care Continuum at 2024 AAOS Annual Meeting
WILMINGTON, DE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology company, will showcase its latest technologies across the orthopedic care c...
Enovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
Wilmington, DE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that Brady Shirley, President and COO, Ben ...
Enovis to Host Fourth Quarter and Full Year 2023 Conference Call on February 22nd
Wilmington, DE, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and...
Enovis Introduces the DonJoy ROAM™ OA Knee Brace
The newest innovation in unloader braces is comfortable, easy to use and effective. The newest innovation in unloader braces is comfortable, easy to use and effective.
Enovis Completes Acquisition of LimaCorporate S.p.A
WILMINGTON, Del., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology growth company, today announced that it closed ...